Cleveland 200, Cleveland Clinic, Healthcare IT, Jumpstart Evergreen, Jumpstart Focus, Jumpstart Next, North Coast Angel Fund
SironRX Therapeutics was developing novel therapies to promote dermal wound repair and reduce scarring. The company’s therapeutic platform was based on the delivery of Stromal cell-Derived Factor 1 (SDF-1), which has been shown to promote tissue repair by recruiting stem cells to the damaged organ. SDF-1 has also been shown to prevent cell death and promote new blood vessel formation. SironRx Therapeutics has received investment from the North Coast Angel Fund, Cleveland Clinic, and Jumpstart Next, Evergreen, and Focus Funds.